Home    Contact Us    Links    Forms   


Henry D. Coleman

Henry D. Coleman has been in patent practice since 1985, with an emphasis on high technology chemistry, pharmaceuticals, biotechnology, polymers, cosmetics, medical devices and instrumentation.  His client base includes Fortune 500 companies, major universities, publicly traded high technology companies, private equity and venture capital groups, small companies and individual inventors.



Dr. Coleman graduated from the State University of New York at Buffalo in 1977 with a B.S. in Pharmaceutical/Medicinal Chemistry (magna cum laude) and a B.A. in Political Science (magna cum laude), and in 1982 with a Ph.D. in Pharmaceutical/Medicinal Chemistry. Dr. Coleman attended the University of Wisconsin School of Law, graduating in 1985 (cum laude).


Legal Experience:

Dr. Coleman has been engaged as a partner in intellectual property practice since 1987. He has over 30 years of experience in patent procurement and related proceedings, including interferences, before the United States Patent and Trademark Office in a variety of chemical, pharmaceutical, biotechnological and cosmetic technologies. He has extensive negotiating and licensing experience in technology transfer and joint venture research relationships, having negotiated numerous agreements in the areas of cosmetics, pharmaceuticals, biotechnology, medical devices, contact lenses, polymer coatings, paint strippers, printing technology, diagnostics, and related products. Dr. Coleman has patent and contract litigation experience (including arbitration experience) in the technical areas of contact lens copolymers, specialty chemicals, cosmetics and pharmaceuticals. Dr. Coleman also has extensive experience in conducting due diligence and providing opinions on patent matters, including licensing. Dr. Coleman has been counsel in interference proceedings in the U.S. Patent and Trademark Office in the biotechnology and pharmaceutical arts.

Dr. Coleman was a summer associate (1984) with the Boston patent law firm Fish & Richardson where he handled patent prosecution and technology assessment in the biotechnology area (monoclonal antibodies, expression vectors, genetic engineering techniques, DNA probe technology) and was an associate attorney with Kenyon & Kenyon from 1985 to 1987 where he handled patent prosecution, licensing, and opinion-related matters in a number of technical areas including polymer chemistry, polymeric resins, pharmaceuticals, biotechnology, metallurgical products, materials science, cosmetics, medical devices and instrumentation and food technology. Dr. Coleman was also a partner in the firm McAulay Fisher Nissen Goldberg & Kiel, LLP from 1996-1997 where he practiced intellectual property law primarily in the chemical and pharmaceutical areas.

Dr. Coleman is admitted to practice before the United States Patent and Trademark Office, the United States District Courts for the Southern District of New York and the Eastern District of New York, and before the Appellate Courts of the States of New York.


Related Legal Experience:

Dr. Coleman has served as a patent expert witness (Hamman & Benn, Chicago, Ill., 1995-1997) in a pharmaceutical patent infringement litigation as well as an expert witness (Habush, Habush & Davis, Madison, Wisconsin l984-85) in a medical malpractice case.


Technical Experience:

Dr. Coleman has completed graduate research in synthetic organic chemistry (nucleoside, carbohydrate, and heterocyclic), bio-organic chemistry (RNA and DNA phosphodiester and phosphotriester chemistry), biochemistry/pharmacology (RNA and DNA biochemistry, modified polymeric nucleoside cell uptake studies, cell culture techniques, and RNA and DNA purification), and drug design (design of anti-neoplastic DNA and RNA probes modified with unnatural nucleoside analogs for inhibition of reverse transcriptase and neoplasia). His Ph.D. thesis, "Studies on the Chemical Synthesis of Oligoribonucleotides Containing 5-Mercaptopyrimidine Bases", dealt with research on the design and chemical synthesis of modified deoxyribonucleic acid and ribonucleic acid as anti-cancer agents.

Dr. Coleman has experience in polymer research directing the development of novel gas permeable contact lens polymers, and served as Director of Polymer Research and Development at Permeable Technologies, Inc., directing polymer development in the contact lens area in concert with a joint venture research group from E.I. DuPont de Nemours & Company. He is a former Executive Vice-President of Permeable Technologies, and a co-inventor of three United States patents in the polymer chemistry and soft contact lens technologies

Bar Association and Professional Membership: Admitted in New York, and to the Patent bar. Member, New York Patent, Trademark and Copyright Association, Association of University Technology Managers and the American Chemical Society.